Many therapies for the reduction of triglycerides have issues of safety or convenience. Astaxanthin, however, reduces elevated triglycerides in a multi-faceted, quantifiable, and safer manner.
Fibric acid derivatives exhibit well-documented risks of adverse effects when used in combination with statins. Newer drugs such as purified derivatives of the omega-3 fatty acids must be taken at very high doses and some increase LDL-C concomitant with induced liver stress. In contrast, astaxanthin not only shows significant triglyceride and LDL-C lowering capability, at much lower, more manageable doses, but it also lowers key markers of inflammation such as TNF-α and raises HDL-C and adiponectin in humans.